In a significant victory for stockholders, Pomerantz LLP led by Partner Gustavo F. Bruckner, secured a groundbreaking settlement on behalf of Douglas Elliman Inc. (“Douglas Elliman”), addressing allegations former members of senior management and the Douglas Elliman Board of Directors failed to ensure that the Company had in place reporting systems that would have put them on notice of sexual misconduct by two former top brokers, Tal and Oren Alexander (the “Alexander Brothers”).
Plaintiff filed suit on behalf of nominal defendant Douglas Elliman, a prominent real estate services company, following a series of public revelations that, during their tenure at the Company, the Alexander Brothers perpetrated extensive and appalling sexual misconduct, including drugging, sexual assault, and sex trafficking. Prior to filing suit, Pomerantz spent nearly a year investigating the circumstances surrounding the allegations in this Action, including an extensive books and records investigation pursuant to 8 Del. C. § 220, resulting in Pomerantz receiving internal, non-public Douglas Elliman documents regarding the Alexander Brothers.
Procedural History
The case commenced on November 14, 2025, when plaintiff filed a 159-page stockholder derivative complaint under seal naming certain of Douglas Elliman’s Board members as well as Douglas Elliman’s former CEO, President, and Chairman, Howard M. Lorber, as defendants. In the Complaint, plaintiff alleged that the Board and management ignored allegations that should have warned them that the Alexander Brothers had engaged in severe misconduct. The Complaint also claimed that the Company was harmed following the revelation of the Alexander Brothers’ misconduct by virtue of, among other things, settlements with former agents and the loss of top brokers to competitors.
Following mediation, the parties reached an agreement-in-principle on January 20, 2026, with the final stipulation executed on February 19, 2026.
Settlement Terms
On July 7, 2026, Vice Chancellor Lori W. Will approved a settlement delivering substantial monetary and governance reforms, including:
- Monetary Component: The Individual Defendants’ insurers will pay $17.5 million to Douglas Elliman.
- Board Expansion: The Board will nominate two additional independent directors to augment the existing five-member Board.
- De-staggering the Board: The Board will, no later than the Company’s 2027 annual meeting of stockholders, seek stockholder approval for a proposal requiring every director to stand for reelection annually
- Adoption of a New Clawback Policy: The Board adopted a new Discretionary Compensation Clawback Policy which will prevent Douglas Elliman executive officers from retaining incentive compensation after committing a material violation of federal or state law related to their service to the Company or if the conduct rises to the standard of bad faith under Delaware corporate law.
- Employee-level Changes: The Settlement requires significant revisions to the Company’s policies governing discrimination, harassment, sexual harassment, retaliation, and other serious improper conduct.
- Reporting Mechanisms: The Settlement requires strengthened reporting and escalation procedures.
- Board Oversight: The Settlement requires Board-level or Board-committee oversight of serious misconduct matters.
- Mitigating Conflicts: The Settlement strengthens procedures to address potential conflicts in responding to allegations of misconduct.
- Company-wide Training: The Settlement requires the Company to provide training regarding the revised policies and procedures.
- Timeframe: The Settlement imposes continuing obligations on the Company for as long as Douglas Elliman remains an independent public company.
This settlement represents a landmark achievement for Douglas Elliman and its stockholders, providing a meaningful monetary payment to remedy past harm suffered by the Company as well as powerful therapeutic relief that ensures strengthened governance and accountability while substantially reducing the chances of similar misconduct occurring in the future.